Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis.

Abstract

Although clinical trials suggest that colchicine may reduce the risk of vascular events in patients with a history of coronary artery disease, its effect on the prevention of cerebrovascular events still remains unclear. A systematic review and meta-analysis was performed of all available randomized controlled trials (RCTs) reporting on incident strokes during the follow-up of patients with a history of cardiovascular disease randomized to colchicine treatment or control (placebo or usual care). Four RCTs were identified, including a total of 5553 patients (mean age 61years, 81% males), with a follow-up ranging from 1 to 36months. Colchicine treatment was associated with a significantly lower risk of incident stroke during follow-up compared to control (risk ratio0.31, 95% confidence interval 0.13-0.71), without heterogeneity across included studies (I2 =0%). Based on the pooled incident stroke rate of control groups (0.9%) in the included RCTs, it was estimated that administration of low-dose colchicine to 161 patients with coronary artery disease would prevent one stroke during a follow-up of 23months. Colchicine treatment decreases stroke risk in patients with a history of coronary artery disease. The effect of colchicine in secondary stroke prevention is currently being evaluated in an ongoing RCT.